Clinical Trials Directory

Trials / Unknown

UnknownNCT05943093

H19 in Acute Lymphoblastic Leukemia.

Expression of Long Non-Coding RNA H19 in Acute Lymphoblastic Leukemia

Status
Unknown
Phase
Study type
Observational
Enrollment
96 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
2 Months – 70 Years
Healthy volunteers

Summary

* Study the expression level of H19 gene in the samples from ALL patients by real-time PCR. * Correlate the expression level of H19 gene with the clinical presentation and laboratory data of those patients.

Detailed description

Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children and adolescents (Zeng XL et al, 2023). ALL is a haematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors (Hong Z et al, 2021). It arises from B- or T-lineage lymphoid progenitors: B-cell-precursor ALL (B-ALL) and T-cell ALL (T-ALL) (Brady SW et al., 2022). Rrelapse in ALL is the fundamental cause of treatment failure in 15-20% of patients (Hulleman E et al, 2009). Therefore, the exploration of novel functional molecules that play a role in ALL pathogenesis could be effective therapeutic targets for this disease (Asadi M et al, 2023). Long non-coding RNAs (lncRNAs) are non-protein coding transcripts longer than 200 nucleotides (Kopp F et al, 2018). H19 was the first lncRNA to be discovered and submitted for genomic imprinting (Yoshimura H et al, 2018). It has a role in embryogenesis and tumorigenesis (Yoshimura H et al, 2014). It also has an indispensable role in enhancing cell proliferation, differentiation, migration, invasion, and chemo resistance (Li Y et al, 2020). Recent evidence has shown that H19 is an oncogene and is overexpressed in breast, liver, endometrial, lung, cervical, and esophageal cancers (Asadi M et al, 2023). A similar pattern of H19 expression was observed in various types of leukemias, including chronic myeloid leukemia (CML) (Morlando M et al, 2015) and acute myeloid leukemia (AML) (Zhang Tj et al, 2018).

Conditions

Timeline

Start date
2023-07-01
Primary completion
2025-07-01
Completion
2025-08-01
First posted
2023-07-13
Last updated
2023-07-13

Source: ClinicalTrials.gov record NCT05943093. Inclusion in this directory is not an endorsement.